Gilead Sciences, Inc. $GILD Holdings Boosted by LGT Fund Management Co Ltd.

LGT Fund Management Co Ltd. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 14.0% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,135 shares of the biopharmaceutical company’s stock after acquiring an additional 3,450 shares during the period. LGT Fund Management Co Ltd.’s holdings in Gilead Sciences were worth $3,119,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Quent Capital LLC lifted its holdings in Gilead Sciences by 32.4% in the second quarter. Quent Capital LLC now owns 3,759 shares of the biopharmaceutical company’s stock worth $417,000 after acquiring an additional 919 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in Gilead Sciences by 6.9% in the second quarter. QRG Capital Management Inc. now owns 299,587 shares of the biopharmaceutical company’s stock worth $33,215,000 after acquiring an additional 19,277 shares during the last quarter. Jackson Wealth Management LLC lifted its holdings in Gilead Sciences by 15.4% in the second quarter. Jackson Wealth Management LLC now owns 4,747 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 633 shares during the last quarter. Stock Yards Bank & Trust Co. lifted its holdings in Gilead Sciences by 1,069.8% in the second quarter. Stock Yards Bank & Trust Co. now owns 25,220 shares of the biopharmaceutical company’s stock worth $2,796,000 after acquiring an additional 23,064 shares during the last quarter. Finally, Ascent Group LLC lifted its holdings in Gilead Sciences by 52.7% in the second quarter. Ascent Group LLC now owns 49,324 shares of the biopharmaceutical company’s stock worth $5,469,000 after acquiring an additional 17,016 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $112.69 on Friday. Gilead Sciences, Inc. has a 12 month low of $83.98 and a 12 month high of $121.83. The stock has a market cap of $139.83 billion, a price-to-earnings ratio of 22.45, a PEG ratio of 0.75 and a beta of 0.34. The stock’s 50 day moving average price is $114.34 and its 200 day moving average price is $109.92. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the company earned $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s payout ratio is 62.95%.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Saturday, September 27th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.